Piramal Pharma Limited Fiscal Year 2026 Financial Results and Leadership Appointments

Piramal Pharma Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. Alongside its financial performance, the company announced key leadership re-appointments, including Chairperson Ms. Nandini Piramal and Executive Director Mr. Peter DeYoung. Additionally, the company appointed Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer, effective April 29, 2026, as part of its ongoing corporate governance initiatives.

Financial Performance Overview

For the financial year ended March 31, 2026, Piramal Pharma Limited reported standalone revenue from operations of ₹4,782.01 crore, compared to ₹5,285.71 crore in the previous year. On a consolidated basis, annual revenue reached ₹8,869.08 crore. The company reported a consolidated net loss of ₹325.94 crore for the year, primarily influenced by exceptional items and an impairment charge of ₹175.82 crore recognized during the annual assessment under IND AS 36.

Leadership Re-appointments

The Board of Directors has approved several key leadership continuity measures, subject to shareholder approval:

  • Ms. Nandini Piramal has been re-appointed as Whole-Time Director, designated as Executive Director and Chairperson, for a period of three years effective April 1, 2027.
  • Mr. Peter DeYoung has been re-appointed as Whole-Time Director, designated as Executive Director, for a period of three years effective October 6, 2026.
  • Mr. Sridhar Gorthi and Mr. Peter Stevenson have been re-appointed as Non-Executive, Independent Directors for a second term of five years, effective March 30, 2027.

Strategic Corporate Changes

Effective April 29, 2026, Mr. Maneesh Sharma will assume the role of Company Secretary and Compliance Officer, taking over from Ms. Pratibha Mishra. Furthermore, the company has announced a change in the address of its registered office, which will move to Ananta Building, Piramal Corporate Park, Kurla (West), Mumbai, effective April 30, 2026. These changes reflect the company’s commitment to strengthening its internal governance and operational infrastructure.

Source: BSE

Previous Article

Piramal Pharma Limited Q4 & FY26 Audited Financial Results and Board Appointments

Next Article

Piramal Pharma Limited Fiscal Year 2026 Results Reflect Transitional Period and Strategic Growth